2025
Price M, Suh M , Pastula S , Kruchko C, Ostrom Q. Pediatric low-grade glioma (pLGG) incidence in the United States from 2015 through 2019. Abstract LGG-04, Society for NeuroOncology (SNO) Pediatric Neuro-Oncology Conference, San Diego, CA, May 2025.
View Abstract
Topics: Cancer , pediatric low-grade glioma (pLGG)
2024
Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693 . ISPOR Europe 2024, November 2024.
View Abstract
Topics: Metachromatic leukodystrophy (MLD)
Haselkorn T, Hughes W, Lennox A, Schara-Schmidt U, Roca A, Miller B, Jensen I , et al. Real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. ISPOR EU 2024 (Top 5% Finalist).
View Abstract
Topics: XLMTM
Haselkorn T, Roca A, Miller B, Jensen I , Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, 19–23 November 2024.
Topics: XLMTM
Suh M , Mittal L, Brorby G, Pastula S, Vincent M, Proctor D. Epidemiology is critical in advancing cumulative impact assessment (CIA) research: A pilot study in San Antonio, Texas. International Society of Exposure Science, Montreal, Canada, October 2024.
View Abstract
Topics: Air Quality , Epidemiology
Kelsh M , Bylsma LC, Jiang X, Movva N , Sacks NC . To be an orphan disease or not to be: An evaluation of prevalence estimates for cancers near the orphan status threshold and implications for orphan drug planning. International Society for Pharmacoepidemiology, 40th Annual Meeting, Berlin, Germany, August 2024.
Topics: Epidemiology , Health Economics and Outcomes Research (HEOR)
Pang F, Dean R, Jensen I , Bean K, Fields C, Miller B. The 18-effectiveness of atidarsagene autotemcel (ARSA-CEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain, ISPOR Europe 2024, November 2024.
Hernandez L, Davies S, Li C, Reddick E, Jensen I . A cost-consequence analysis of ponatinib versus imatinib in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia in the United States. Abstract EE165 . ISPOR 2024 (Top 5% Finalist) .
View Abstract
Topics: Acute lymphoblastic leukemia
Minshall ME, Liu Y, Wagner A, Jensen IS , Corman S. The cost for of chronic lung allograft dysfunction (CLAD) in lung transplant (LTX) recipients by stage 1-4: A claims database analysis. Abstract EE70 . ISPOR 2024.
View Abstract
Topics: Chronic Lung Allograft Dysfunction (CLAD) , cost-utility analysis , Health Economics and Outcomes Research (HEOR)
Vincent M , Fitch S , Bylsma L , Thompson C , Rogers S , Britt J , Wikoff D . Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology 63rd Annual Meeting, Salt Lake City, UT, March 2024.
View Abstract
A Division of